

PATENT *ITW*

Atty. Docket No. 20426.003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nicholas M. Valiante et al.

Serial No.: 10/814,480

Group Art Unit: to be assigned

Filed: March 29, 2004

Examiner: to be assigned

For: USE OF SMALL MOLECULE COMPOUNDS FOR
IMMUNOPOTENTIATION**INFORMATION DISCLOSURE STATEMENT**
UNDER 37 CFR §1.56 AND §1.97(b)(3)Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The following is an Information Disclosure Statement submitted for the Examiner's consideration pursuant to 37 CFR §1.56 and §1.97.

The information listed on the enclosed PTO 1449 form was cited in the International Search Report for International Application No. PCT/US2004/010331 mailed September 27, 2004, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, indicating the degree of relevance found by the foreign office, is enclosed herewith. Copies of the references are submitted herewith. The Examiner is requested to make the information of official record in the application.

Applicants have enclosed the completed PTO-1449 form and would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


This Information Disclosure Statement under 37 C.F.R §1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 USC §102.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11 day of October, 2004.
By [Signature]

Applicants believe no fee is required for this filing. If a fee is required, however, the Commissioner is authorized to charge such fee to Deposit Account No. 03-1664.

Respectfully submitted,

By:



Steven W. Collier
Attorney for Applicants
Reg. No. 42,429

October 5, 2004

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-3774
(510) 655-3542 (fax)

OYFE
 OCT 14 2004
 JCI0530
 PATENT & TRADEMARK OFFICE

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCLOSURE CITATION		Applicants: Valiante <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: March 29, 2004	Group: to be assigned

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	2002/0022624	02/21/02	Dinnell <u>et al.</u>			

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
	BA	WO 00/12074	03/09/00	PCT				
	BB	WO 02/22598	03/21/02	PCT				
	BC	WO 00/76505	12/21/00	PCT				
	BD	WO 01/64668	09/07/01	PCT			(abstract only)	
	BE	WO 02/090375	05/02/01	PCT				
	BF	WO 02/083624	10/24/02	PCT				
	BG	WO 03/000694	01/03/03	PCT				
	BH	WO 00/59904	10/12/00	PCT				

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA		Sato <u>et al.</u> , "Characteristics of Antitumor Activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- . . ." <u>Cancer Letters</u> 91:1-9, 1995
	AB		Oyaizu <u>et al.</u> , "Inhibition of CD4 Cross-Linking-Induced Lymphocytes Apoptosis by Vesnarinone as a Novel Immunomodulating Agent . . ." <u>Blood</u> 87(6):2361-2368, March 15, 1996
	AC		Toldy <u>et al.</u> , "3,4,5-Trimethoxybenzoylderivative, Eine Neue Verbindungsgruppe Mit Antiulzerogener Wirkung" <u>Acta Chimica Academiae Scientiarum Hungaricae Tomus</u> 49(3):265-286, 1966
	AD		Sato <u>et al.</u> , "Induction of Tumour Differentiation and Apoptosis and Le ^y Antigen Expression in Treatment with Differentiation-Inducing Agent, Vesnarinone, of a Patient with Salivary Adenoid Cystic Carcinoma" <u>Apoptosis</u> 2:106-113, 1997
	AE		Petigara <u>et al.</u> , "Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives" 11:332-336, March 1, 1968
	AF		Yamaguchi, "Vesnarinone Inhibits Growth of Large Cell Lung Cancer Cell Lines via Induction of Apoptosis" <u>Med. J. Kagoshima Univ.</u> 51(4):67-75, February, 2000
Examiner			Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.